Immunological parameters as a new lead in the diagnosis of ovarian cancer

被引：0
|
作者：
Baert, T. [1 ,2 ]
Timmerman, D. [1 ,3 ]
Vergote, I. [1 ,2 ]
Coosemans, A. [1 ,2 ]
机构：
[1] UZ Leuven, Gynaecol & Obstet, B-3000 Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Oncol, Leuven Canc Inst, B-3000 Leuven, Belgium
[3] Katholieke Univ Leuven, Dept Dev & Regenerat, B-3000 Leuven, Belgium
来源：
FACTS VIEWS AND VISION IN OBGYN | 2015年 / 7卷 / 01期
基金：
比利时弗兰德研究基金会;
关键词：
Ovarian cancer; diagnosis; prognostic marker; immunosuppression; regulatory T cell; myeloid derived suppressor cells; tumor-associated macrophages;
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Ovarian cancer is the leading cause of pelvic gynecological cancer death in Europe. Prognosis is poor in women diagnosed at stage III to IV or in case disease recurs. Platin-based chemotherapy and radical surgery have already improved prognosis significantly. Novel strategies in the treatment of ovarian cancer are being searched for. The study of the immune system as a valuable parameter in the development of ovarian cancer has been neglected for a long time. Nevertheless, this is a field in full progression and might open new perspectives in the diagnosis and prognosis of ovarian cancer patients and could lead to a more motivated choice of targeted therapies.
引用
收藏
页码：67 / 72
页数：6
相关论文
共 50 条
  • [21] VALUE OF IMMUNOLOGICAL PARAMETERS FOR DIAGNOSIS OF ARTHROPATHIC PSORIASIS
    APOSTOLOFF, E
    SCHULZE, P
    MIELKE, F
    HIEPE, F
    STILLER, M
    ZEITSCHRIFT FUR KLINISCHE MEDIZIN-ZKM, 1989, 44 (16): : 1397 - 1400
  • [22] New Hypothesis on Pathogenesis of Ovarian Cancer Lead to Future Tailored Approaches
    Rescigno, P.
    Cerillo, I.
    Ruocco, R.
    Condello, C.
    De Placido, S.
    Pensabene, M.
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [23] NEW LEAD STRUCTURES IN THE ISOXAZOLE SYSTEM: RELATIONSHIP BETWEEN QUANTUM CHEMICAL PARAMETERS AND IMMUNOLOGICAL ACTIVITY
    Maczynski, Marcin
    Ryng, Stanislaw
    Artym, Jolanta
    Kocieba, Maja
    Zimecki, Michal
    Brudnik, Katarzyna
    Jodkowski, Jerzy T.
    ACTA POLONIAE PHARMACEUTICA, 2014, 71 (01): : 71 - 83
  • [24] Current situation and new perspectives on the early diagnosis of ovarian cancer
    Mauricette Derchain, Sophie Francoise
    Duarte-Franco, Eliane
    Sarian, Luis Otavio
    REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2009, 31 (04): : 159 - 163
  • [25] External validation of a new logistic model in the diagnosis of ovarian cancer
    Guerriero, S
    Ajossa, S
    Boi, M
    Melis, GB
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 190 (01) : 292 - 293
  • [26] Immunonutrition in ovarian cancer: clinical and immunological impact?
    Ferrero, Annamaria
    Vassallo, Daniela
    Geuna, Massimo
    Fuso, Luca
    Villa, Michela
    Badellino, Enrico
    Barboni, Martina
    Coata, Paola
    Santoro, Nathalie
    Delgado Bolton, Roberto C.
    Biglia, Nicoletta
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2022, 33 (06)
  • [27] Immunological aspects of ovarian cancer: Therapeutic perspectives
    Nayama, M.
    Collinet, P.
    Salzet, M.
    Vinatier, D.
    JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION, 2016, 45 (09): : 1020 - 1036
  • [28] Specific keynote: Immunological therapy for ovarian cancer
    Berek, JS
    Dorigo, O
    Schultes, B
    Nicodemus, C
    GYNECOLOGIC ONCOLOGY, 2003, 88 (01) : S105 - S109
  • [29] Immunological analogies between ovarian cancer and pregnancy
    Hanssen, S.
    Collinet, P.
    Leblanc, E.
    Salzet, M.
    Vinatier, D.
    JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION, 2013, 42 (03): : 217 - 226
  • [30] BIOLOGIC AND IMMUNOLOGICAL THERAPY OF OVARIAN-CANCER
    BOOKMAN, MA
    BEREK, JS
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1992, 6 (04) : 941 - 965
12345